Diagnostic Imaging

Guidelines 2021

Japan Radiological Society



Kanehara & Co., Ltd.

Introduction

The purpose of the diagnostic imaging guidelines is to ensure that medical care that uses diagnostic imaging is justified, optimized, performed effectively and efficiently, grounded in science to the greatest extent possible, and that its outcome is beneficial to the patient. Since the 2013 edition, the guidelines have been provided in the form of clinical questions (CQs) and recommendation grades for the different fields. Progress in diagnostic imaging has been rapid, and immediately after the 2016 edition was published, work on the next revision began. The current revision was made possible through the efforts of all members of the guidelines committee, particularly the committee chair, Dr. Murayama.

The previous belief about medical research was that the level of evidence from randomized, controlled studies was high, whereas the level of evidence from diagnostic imaging tended to be weak because it was based on cross-sectional studies. Moreover, evidence from imaging procedures for which multicenter, randomized, controlled studies could be performed and that used technology that was already widely used (somewhat older) was considered stronger than evidence from clearly superior, cutting-edge, imaging procedures (e.g., in detecting stroke, CT had stronger evidence than diffusion-weighted MRI). In the rapidly advancing field of diagnostic imaging, this left the impression of being removed from the current reality. Consequently, the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system has been incorporated for the first time to bring the guidelines in line with reality.

Although the target audience for the 2016 edition of the guidelines was mainly diagnostic radiology specialists, the target audience of the present guidelines is general practitioners, who order imaging procedures. Japan has the highest number of CT and MRI systems per capita. On the one hand is the view that the government and citizenry understand the importance of diagnostic imaging, and it is therefore widely used. On the other is the criticism that there is often inadequate justification for imaging procedures, as indicated by the fact that CT exposure in Japan is the highest in the world, and that CT needs to be used appropriately. The number of radiologists per capita is smaller in Japan than in other countries, suggesting that diagnostic imaging guidelines aimed at the general practitioner could play a major role in encouraging the appropriate use of imaging procedures.

A questionnaire survey of radiologists at a training facility for radiology specialists on compliance with the 2016 edition of the diagnostic imaging guidelines showed that, although many procedures were performed according to the recommendations, a considerable number of tests that were not recommended were also performed (Fig.; Kumamaru KK et al: Jpn J Radiol 35: 648-659, 2017). It is hoped that these general practitioner-oriented guidelines will be used widely, and that imaging procedures will be used appropriately, leading not only to improvements in the quality of medical care and outcomes for patients, but also appropriate restraints on medical costs.



Figure Frequency of non-recommended imaging procedures (Japan Radiological Society appropriate-use survey, 2017)

September 2021 Shigeki Aoki President, Japan Radiological Society

Formulation of the 2021 Diagnostic Imaging Guidelines

As with the previous edition (2016 edition), I was appointed a committee chair and engaged in formulating the guidelines. In the 5 years since the previous edition was published, there have been several developments that have had a major impact on the context in which clinical practice guidelines are developed. First, to ensure consistency among the guidelines proposed by the various academic societies, the Japanese Association of Medical Sciences established a clinical practice guidelines management committee, and the societies were required to coordinate their efforts in developing clinical practice guidelines. One aspect of this was disclosing any conflicts of interest on the part of committee members who develop clinical practice guidelines and setting forth a policy stipulating that individuals with commercial conflicts of interests in excess of what is allowed should not serve as a chairperson or member of a guidelines development committee. With regard to the present guidelines, the Japan Radiological Society was notified of the presence or absence of any conflicts of interest held by the individuals who developed the guidelines, and this information was publicly disclosed on the society's website. Another aspect was consolidating the target readership of the clinical practice guidelines. During management committee meetings, the decision was made to target the guidelines at physicians belonging to key academic societies. The previous edition of the diagnostic imaging guidelines was aimed at diagnostic radiology specialists and was developed to serve as a guide for radiologists who provide advice on the usefulness of an imaging procedure when one was requested in the clinical setting. However, the present edition is aimed at physicians affiliated with key academic societies and was developed to serve as a guide when requesting an imaging procedure. In other words, the previous guideline has been changed to information that is more suitable for the medical treatment site.

Moreover, in the previous edition, the recommendation grades took into account evidence-based medicine (EBM) levels based on the MINDS Manual for Guideline Development 2007. For the present edition, a 4-step assessment was performed incorporating the GRADE system (explained in Overview section 2, Preparing the Diagnostic Imaging Guidelines) for the clinical questions (CQs), based on the MINDS Manual for Guideline Development 2017. In the previous edition, grade C1, "procedure recommended, although there is no scientific basis for performing it," was the most common grade, and this was limited to assessments indicating that the procedure could be performed because adequate evidence was lacking. In the present edition, many of these assessments were changed to "weakly recommended" under the GRADE system. In brief, this was because it enabled the assessments to reflect not only the evidence, but also the clinical importance of the procedure.

The many physicians on the subcommittees for the different fields expended considerable effort in developing the present guidelines, starting with the numerous training sessions on the GRADE system held at the headquarters of the Medical Information Distribution Service (MINDS) and extending to development of the background questions (BQs), clinical questions (CQs), and future research questions

(FQs) for each field. In addition, the physicians on the central committee, particularly Dr. Masako Kataoka of Kyoto University and Dr. Yuko Iraha of the University of the Ryukyus, oversaw all aspects of the preparation of the guidelines, from inception to publication. Furthermore, assistance was provided through the publication stage by the physicians who served as advisors, those from other academic societies who provided assessments as outside committee members, and many other physicians. We are deeply grateful to everyone involved.

September 2021 Sadayuki Murayama Chair, Clinical Practice Guidelines Committee, Japan Radiological Society

Overview of the 2021 Diagnostic Imaging Guidelines

1 Purpose of the guidelines

The purpose of these guidelines is to help ensure that medical care that uses diagnostic imaging is provided effectively, efficiently, and in a manner that benefits the patient in terms of outcomes. The guidelines are based on evidence-based medicine (EBM; i.e., using the latest and best evidence in making diagnostic imaging decisions for the individual patient in a conscientious, clear, and prudent manner) related to diagnostic imaging performed in a variety of fields. Indications for diagnostic imaging and the effectiveness of diagnostic imaging, particularly standard imaging methods, are discussed in detail.

2 Revisions

The diagnostic imaging guidelines were prepared based on EBM methods by the Japanese College of Radiology in 2003 and as a joint project by the Japan Radiological Society and Japanese College of Radiology in 2007 and 2013. Since the 2016 edition ("previous edition" below), the Japan Radiological Society has assumed responsibility for the project and prepared the guidelines based on the MINDS Manual for Guideline Development 2007. The 2021 edition ("present edition" below) represents a major revision that, based on the MINDS Manual for Guideline Development 2017,²⁾ incorporates the GRADE system.³⁾ The standard imaging methods for each field were updated with the addition of the 3T-MRI and 64-row CT imaging methods. Moreover, in addition to the 9 fields covered in the previous edition, new sections were created for the fields of pediatrics and hematology. Through the previous edition, the target audience was diagnostic imaging specialists. However, the present edition was created with physicians affiliated with key academic societies in mind.

3 Intended users

In developing the present edition, an effort was made to ensure that the content is easy to use for physicians affiliated with the key academic societies, as well as for those who specialize in diagnostic imaging (specialists). It was also intended as a reference for paramedical staff such as radiology technologists.

4 Usage notes

The guidelines strictly represent the guidance considered standard when they were developed. They do not regulate actual medical practice, and they should be used flexibly and in a manner that takes into account the healthcare environment (personnel, experience, facilities, etc.) and the individual patient.

Although the academic society assumes responsibility for the content of the guidelines, responsibility for treatment outcomes lies with those directly providing the medical care. Neither the Japan Radiological Society nor the members of the guidelines development committee bear any responsibility for such outcomes. Use of the guidelines as examination criteria for health insurance or as reference material in medical practice disputes or medical lawsuits would be an obvious deviation from the purpose of clinical practice guidelines.

5 Organization of the present edition and the formulation process

As was mentioned above, the first edition of these guidelines was published in 2003, and revisions have since been made as appropriate. The guidelines, which cover all areas where diagnostic imaging is used, are organized according to 11 fields (14 fields when the digestive organs field is subclassified): neuroradiology, head and neck, chest, cardiovascular, digestive organs (liver, hepatobiliary, pancreas, and gastrointestinal tract), uroradiology, obstetrics and gynecology, breast, musculoskeletal, pediatrics, and hematology. Since the previous edition, the organization responsible for preparing and revising the guidelines has been the Japan Radiological Society, with the society's standing diagnostic imaging guidelines committee actually preparing and revising the guidelines. The guidelines committee consists of central committee members who coordinate and assist in all fields and 14 subcommittees, one for each field.

In implementing the present revision, new committee members were appointed, and the work began in April 2018. At the first guidelines committee meeting (April 2018), the decision was made to prepare the guidelines based on the GRADE system,³⁾ which was recommended by the EBM promotion program (MINDS) being implemented by the Japan Council for Quality Health Care. Subsequently, through May 2019, approximately 100 committee members participated in on-demand seminars on preparing clinical practice guidelines organized by MINDS, where they learned about the process of preparing CQs using the GRADE system. At the fourth meeting of the guidelines committee (June 2019), it was decided that each subcommittee would reorganize the 171 CQs of the previous edition by dividing them into CQs, BQs, and FQs and retaining or discarding items or creating new CQs, BQs, and FQs as necessary (see Overview section 2, Developing the diagnostic imaging guidelines). The final CQs, BQs, and FQs for each area were determined by the fifth meeting of the guidelines committee (October 2019). The members of each subcommittee responsible for BQs and FQs began writing, adding articles published through June 2019 to the cited references. However, if an article published after June 2019 provided important findings that were related to a recommendation grade, it was added as appropriate at the discretion of the subcommittee members. The previous edition provided the evidence level proposed by the Oxford EBM Centre for each cited reference. In the present edition, however, because the quality of evidence grade based on the GRADE system³⁾ was used (see next section 6), the evidence level for each cited reference was not indicated to avoid confusion. CQ-related literature searches were performed using the PubMed database, with the assistance of the Japan Medical Library Association. The period searched was January 1, 2016 to June 30, 2019. If the search results were inadequate, the search queries were modified, and additional searches were performed by each subcommittee. The subcommittee members responsible for systematic reviews (SRs) of the CQs selected by each subcommittee participated in an SR workshop for the radiological society (February 2020) organized by Cochrane Japan in order to gain an understanding of the specific tasks involved in SRs. Substantive SR work began in August 2020, when the Japan Medical Library Association finished collecting literature. Between January 2021 and March 2021, the subcommittees met to determine recommendation grades (all meetings held online due to the coronavirus pandemic) and decided on the grade for each CQ. The designated subcommittee members wrote the CQ explanations based on these decisions.

6 Strength of Recommendation, quality of evidence grade (strength), and agreement rate based on the GRADE system

The recommendation strength in the present edition determined the degree to which a procedure was recommended. It was based not only on the scientific evidence presented in the previous edition, but also factors such as the balance between the benefits and harms that result from intervention in routine clinical practice, the consistency of the patients' wishes, and economic considerations. The strength of the evidence was rated on a 4-step scale according to the MINDS Manual for Guideline Development 2017,²⁾ with the Clinical Practice Guidelines for Breast cancer 2018 used as a reference (Table 1).⁴⁾ The strength ratings roughly correspond to the recommendation grades of A, B, C1, C2, and D that were used through the previous edition. In the text of the recommendations, the quality of the evidence was indicated according to 4 steps: high, moderate, low, and very low (Table 2). For all of the outcomes specified for each CQ, the recommendation is considered strong in proportion to the strength of the evidence. The quality of evidence reflects the extent to which our confidence in an estimate of the effect is adequate to support a particular recommendation.

The reason for indicating the agreement rates (%) in the meetings held to determine recommendations is that a recommendation grade of "weakly recommended," for example, would have different implications if the agreement rate were 100% than if it were 73%. The authors hope that the users will understand that a small number of panel members were leaning toward strongly recommending the procedure or toward weakly recommending not performing it, and to refer to it as useful information in actual diagnostic intervention. In addition, knowing whether the decision was made with a single vote or if agreement was reached after multiple votes enables the user to understand whether there are differences of opinion. In other words, when shared decision-making is practiced in the clinical setting, it would be preferable to share with the patient the fact that there are differences of opinion among specialists before determining the ultimate means of intervention. If agreement was not reached after 3

votes, "agreement not reached" was indicated for the agreement rate. Because the agreement rate indicates where opinions diverged, the authors hope that the users will refer to such information in determining the means of intervention.

| Recommendation Strength | ecommendation Strength Recommendation Text | |
|----------------------------|---|-------|
| 1 | Strongly recommend performing | А |
| 2 | Weakly recommend performing | B, C1 |
| 3 | Weakly recommend not performing | C2 |
| 4 | Strongly recommend not performing | D |

Table 1. Strength of Recommendation

When both performing and not performing were difficult to recommend, "no recommendation" was indicated.

| [able 2. Quality of Evidence Grad | des (strength) for a recommendation |
|-----------------------------------|-------------------------------------|
|-----------------------------------|-------------------------------------|

| A: High | We are very confident that the true effect lies close to that of the estimate of the effect. |
|-------------|--|
| B: Moderate | We are moderately confident in the effect estimate. |
| C: Low | Our confidence in the effect estimate is limited. |
| D: Very Low | We have very little confidence in the effect estimate. |

7 Third-party evaluations

In implementing the present revision, third-party evaluations were obtained by sending a draft indicating the standard imaging methods, BQs, CQs, and FQs for each field to the academic societies listed in the third-party evaluation list provided below. For the previous edition, a post-publication third-party evaluation was obtained from MINDS, and a post-publication third-party evaluation will continue to be obtained from MINDS for each revision.

8 Funding sources

The Japan Radiological Society bears the entire cost of preparing and revising these guidelines; no outside funding is provided.

9 Conflicts of interest (COIs)

Publication of these guidelines is approved by the Japan Radiological Society, and the society bears the entire cost of preparing and revising the guidelines. No outside funding whatsoever, such as grants or research funding, has been accepted. In accordance with the society's COI rules, the conflict-ofinterest status of all committee members involved in preparing the guidelines (members of the central committee and subcommittees and outside committee members) was determined for the previous 3 years. When voting took place in meetings to determine recommendations, the members self-reported any COIs (economic or academic). If a member was disqualified due to a COI, the member abstained from voting on that CQ in an effort to avoid biased opinions. The COI status of each committee member is indicated on the Japan Radiological Society website (http://www.radiology.jp/).

10 Future plans

The guidelines will be published in print by Kanehara & Co., Ltd. and subsequently released on the Japan Radiological Society website.

- 1) MINDS Clinical Practice Guidelines Selection Working Group, Ed.-in chief: MINDS Manual for Guideline Development 2007. Igaku-Shoin Ltd., 2007.
- 2) Kojimahara N, et al., Ed.: MINDS Manual for Guideline Development 2017. Japan Council for Quality Health Care, 2017.
- 3) GRADE: The grading of recommendations assessment, development and evaluation (https://www.gradeworkinggroup.org)
- 4) The Japanese Breast cancer Society Clinical Practice Guidelines for Breast cancer 2018

Guidelines Development Committee Members

University of the Ryukyus 【Chair】

University of the Ryukyus

Dokkyo Medical University

Nihon University

Kyoto University

Juntendo University

Tohoku University

Tohoku University

Tohoku University

Nippon Medical School

Indicated in Japanese syllabary order for each field

Central committee

Sadayuki Murayama Yuko Iraha Masahiro Okada Yasushi Kaji Masako Kataoka Kanako Kumamaru Kei Takase Hiromitsu Hayashi Naoko Mori Yohei Morishita Yasuyuki Yamashita

Overv

| Yasuyuki Yamashita | Kumamoto University | |
|--------------------|--------------------------------------|--|
| Overview authors | | |
| Noriko Aida | Kanagawa Children's Medical Center | |
| Kazuko Ohno | Kyoto College of Medical Science | |
| Masako Kataoka | Kyoto University | |
| Yasuo Takehara | Nagoya University | |
| Yasuo Nakajima | St.Marianna Univ. School of Medicine | |
| Hiromitsu Hayashi | Nippon Medical School | |
| Yoshiyuki Watanabe | Shiga University of Medical Science | |

Subcommittees by field

Neuroradiology

| Toshinori Hirai | Kumamoto University 【Chair】 |
|--------------------|---|
| Kazunari Ishii | Kindai University |
| Hiroshi Oba | Teikyo University |
| Mitsunori Kanagaki | Hyogo Prefectural Amagasaki General Medical Center |
| Kohsuke Kudo | Hokkaido University |
| Noriko Sato | National Center of Neurology and Psychiatry |
| Yuki Shinohara | Akita Research Institute of Brain and Blood Vessels |
| Toshiaki Taoka | Nagoya University |
| Masayuki Maeda | Mie University |
| Harushi Mori | Jichi Medical University |
| Kei Yamada | Kyoto Prefectural University of Medicine |
| Yoshiyuki Watanabe | Shiga University of Medical Science |

Head and Neck

Hiroki Kato Ryutaro Ukisu Hiroya Ojiri Nobuo Kashiwagi Naoko Saito Akira Baba Takashi Hiyama Akifumi Fujita Daisuke Yunaiyama

Chest

Kazuto Ashizawa Tae Iwasawa Katsunori Oikado Katsuya Kato Takeshi Kamitani Suzushi Kusano Shuji Sakai Hiromitsu Sumikawa Nobuyuki Tanaka Shin Tsutsui Takahiko Nakazono Hideyuki Hayashi Shin Matsuoka Hidetake Yabuuchi

Cardiovascular

Norihiko Yoshimura Masaki Ishida Daisuke Utsunomiya Hideki Ota Seitaro Oda Kakuya Kitagawa Kido Masafumi Akira Kurata Eijun Sueyoshi Fuminari Tatsugami **Ryoichi Tanaka** Yuki Tanabe Seiji Tomiguchi Yoshitake Yamada Kenichi Yokoyama **Kunihiro Yoshioka**

Gifu University 【Chair】 Kitasato University The Jikei University School of Medicine Osaka University Juntendo University The Jikei University School of Medicine National Cancer Center Hospital East Haga Red Cross Hospital Tokyo Medical University Hachioji Medical Center

Nagasaki University 【Chair】 Kanagawa Cardiovascular and Respiratory Center The Cancer Institute Hospital of JFCR Kawasaki Medical School General Medical Center Kyushu University Hitachi Health Care Center Tokyo Women's Medical University Kinki-Chuo Chest Medical Center Yamaguchi-Ube Medical Center Nagasaki University Saga University Isahaya General Hospital St. Marianna University School of Medicine Kyushu University

Niigata City General Hospital 【Chair】 Mie University Yokohama City University Tohoku University Kumamoto University Mie University Kumamoto University Shikoku Cancer Center Nagasaki University Hiroshima University Iwate Medical University Ehime University Japanese Red Cross Society Kumamoto Health Care Centaer Keio University Kyorin University Iwate Medical University

Digestive organs: Liver

| Utaroh Motosugi | Kofu-Kyoritsu Hospital [Chair] |
|-------------------|--|
| Masaaki Akahane | International University of Health and V |
| Shintaro Ichikawa | Hamamatsu University School of Medic |
| Tomoaki Ichikawa | Gunma University |
| Kazuhiko Ueda | The Cancer Institute Hospital of JFCR |
| Hiromitsu Onishi | Osaka University |
| Satoshi Kobayashi | Kanazawa University |
| Tomoko Hyodo | Kindai University |
| Masakazu Hirakawa | Kyushu University Beppu Hospital |
| Satoshi Funayama | University of Yamanashi |
| Masatoshi Hori | Kobe University |
| Hiroyuki Morisaka | University of Yamanashi |
| Akira Yamada | Shinshu University |
| Takeshi Yoshikawa | Hyogo Cancer Center |

Digestive organs: Hepatobiliary

Satoshi Goshima Azusa Kitao Hiroshi Kondo Katsuhiro Sano **Keitaro Sofue** Masakatsu Tsurusaki Tatsuvuki Tonan Yuko Nakamura **Akihiro Nishie** Hiroki Haradome Atsushi Higaki Yasunari Fujinaga Norihide Yoneda Kengo Yoshimitsu

Digestive organs: Pancreas

Hiroyuki Irie Kousei Ishigami Dai Inoue Nakamura Shinichi **Shunro Matsumoto** Haruo Watanabe

Digestive organs: Gastrointestinal

Daisuke Tsurumaru **Masanori Imuta** Narumi Taguchi Yusuke Nishimuta Mototaka Miyake

Welfare cine

Hamamatsu University School of Medicine 【Chair】 Kanazawa University Teikyo University Juntendo University Kobe University Kindai University Kurume University Hiroshima University Kyushu University Kitasato University Kawasaki Medical School Shinshu University Kanazawa University Fukuoka University

Saga University [Chair] Kyushu University Kanazawa University Amakusa Medical Center Almeida Memorial Hospital Chuno Kosei Hospital

Kyushu University 【Chair】 Kumamoto University Tamana Central Hospital Kyushu Cancer Center National Cancer Center Hospital

Obstetrics / Gynecology

Yumiko Oishi Tanaka

Mina Asatani Yoshiko Ueno Yuka Okajima Yuki Kamishima Satomi Kitai Eito Kozawa Junko Takahama Mayumi Takeuchi Megumi Takewa Ayako Tamura Takahiro Tsuboyama Yuji Nakamoto Shinya Fujii Yukiko Honda Kenji Matsuzaki Tomoko Manabe

Uroradiology

Satoru Takahashi Yuki Arita Hirotoshi Ito Yoshimitsu Ohgiya Kazuhiro Kitajima Tatsuya Gomi Hiroshi Juri Masahiro Jinzaki **Hiroshi Shinmoto** Mitsuru Takeuchi Nobuvuki Takevama **Tsutomu Tamada** Go Nakai Atsushi Nakamoto Yoshihiko Fukukura Yukiko Honda Nagaaki Marugami Jiro Munechika Kaori Yamada Akira Yamamoto **Kotaro Yoshida Rika Yoshida** Takeshi Yoshizako

Cancer Institute Hospital of Japanese Foundation for Cancer Research [Chair] Niigata Cancer Center Hospital Kobe University

Medical Imaging Sakae The Jikei University School of Medicine Saitama Medical University Higashiosaka City Medical Center Tokushima University Nara Prefecture Seiwa Medical Center Tokyo-Kita Medical Center Osaka University Kyoto University Tottori University Hiroshima University Tokushima Bunri University Ito Municipal Hospital

Kobe University [Chair] Keio University Kajiicho Medical Imaging Center Showa University Hyogo College of Medicine Toho University Ohashi Medical Center Osaka Medical and Pharmaceutical University Keio University National Defense Medical College Radiolonet Tokai Showa University Fujigaoka Hospital Kawasaki Medical School Osaka Medical and Pharmaceutical University Osaka University Kagoshima University Hiroshima University Nara Medical University Showa University Japanese Red Cross Society Kyoto Daiichi Hospital Kawasaki Medical School Kanazawa University Shimane University Shimane University

Breast

Ichiro Isomoto Setsuko Ishihara Mari Kikuchi Kazunori Kubota Mariko Goto Hiroko Satake Misaki Shiraiwa Hiroshi Nakahara Ritsuko Fujimitsu Satoshi Honda Shuichi Monzawa

Musculoskeletal

Takatoshi Aoki Nozomi Oki Shuji Nagata Tamotsu Kamishima Yasuhiro Kawahara Kaoru Kitsukawa Shoichiro Takao Waka Nakata Katsuyuki Nakanishi Taiki Nozaki Eiji Fukuniwa Hajime Fujimoto

Pediatric

Eiji Oguma Noriko Aida Yoshinobu Akasaka Kumiko Ando Mayuki Uchiyama Tatsuo Kono Yutaka Tanami **Chihiro Tani** Yoshiyuki Tsutsumi Motoo Nakagawa Masanori Nishikawa Kumiko Nozawa Yuta Fujii **Rieko Furukawa** Takahiro Hosokawa Mikiko Miyasaka Osamu Miyazaki

St. Francis Hospital 【Chair】
Okayama Saiseikai General Hospital
Cancer Institute Hospital of Japanese Foundation for Cancer Research
Dokkyo Medical University Saitama Medical Center
Kyoto Prefectural University of Medicine
Nagoya University
Kagawa Prefectural Central Hospital
Sagara Hospital Miyazaki
Itoshima Medical Association Hospital
Tokyo Metropolitan Toshima Hospital
Shinko Hospital

University of Occupational and Environmental Health 【Chair】 Nagasaki University Kurume University Hokkaido University Sasebo Kyosai Hospital St. Marianna University Tokushima University Jichi Children's Medical Center Tochigi Osaka International Cancer Institute St Luke's International Hospital PICTORU Izumo Diagnostic Imaging Office Chiba University Hospital

Saitama Children's Medical Center [Chair] Kanagawa Children's Medical Center Hyogo Prefectural Kobe Children's Hospital Kobe City Medical Center General Hospital The Jikei University School of Medicine Tokyo Metropolitan Children's Medical Center Saitama Children's Medical Center Hiroshima City Hospital National Center for Child Health and Development Nagoya City University Osaka Women's and Children's Hospital Kanagawa Children's Medical Center Kanagawa Children's Medical Center Jichi Children's Medical Center Tochigi Saitama Children's Medical Center National Center for Child Health and Development National Center for Child Health and Development

Nuclear Medicine and Hematology

| Tokyo Medical and Dental University 【Chair】 |
|---|
| Kindai University |
| Fukushima Medical University |
| University of Tsukuba |
| Nagasaki University |
| Kurume University |
| Osaka University |
| Kagawa University |
| Tokyo Medical and Dental University |
| |

Advisors

Takeo Nakayama

Kyoto University

Japan Medical Library Association

Shinichi Abe Yu Ootani

Third-Party Evaluators

In implementing the present revision, third-party evaluations were obtained by sending a draft indicating the standard imaging methods, BQs, CQs, and FQs for each field to the academic societies listed below. We are deeply indebted to the physicians who were involved in this effort.

The Japan Neurosurgical Society. Japanese society of neurology Japanese Society of OtoRhinoLaryngology-Head and Neck Surgery Japan Society for Head and Neck Cancer **The Japanese Circulation Society** The Japanese Society for Vascular Surgery **The Japanese Respiratory Society** The Japan Lung Cancer Society The Japan Society of Hepatology Japan Liver Cancer Association **Japan Biliary Association Japan Pancreas Society** The Japanese Urological Association **Japanese Breast Cancer Society** The Japanese Orthopaedic Association The Japan Society of Gynecologic Oncology The Japan Society of Obstetrics and Gynecology Japan Pediatric Society The Japanese Society of Child Neurology The Japanese Society of Pediatric Surgeons Japanese Society of Hematology

(legal status omitted)

Table of Contents

| G | ene | ral | Remarks | 2 |
|---|-----|------------|--|------|
| | 1 | Evi | dence-Based Imaging Test Selection | 2 |
| | 2 | Dev | veloping Diagnostic Imaging Guidelines | 8 |
| | 3 | CT | and MRI in the Radiological and Medical Services in Japan | . 16 |
| | 4 | Cot | ntrast Media Safety Summary of the 2018 Guidelines on the Use of Iodinated | |
| | - | Cor | ntrast Media in Patients with Kidney Disease | |
| | 5 | Eff | ects of Medical Radiation Exposure in Diagnostic Imaging and of | |
| | | Ele | ctromagnetic Fields in MRI | . 33 |
| | 6 | The | Medical Accident Investigation System and Radiological and Medical | |
| | | Ser | vices | . 39 |
| | 7 | Vie | ws and Procedures for Pediatric Diagnostic Imaging | . 44 |
| 1 | N | eur | oradiology | |
| | Sta | anda | rd Imaging Methods for the Brain and Nervous System | . 50 |
| | BÇ | Q 1 | Which imaging examinations are recommended to diagnose subarachnoid hemorrhage? | 57 |
| | BÇ | Q 2 | Which imaging examinations are recommended to diagnose acute intracerebral | |
| | | | hemorrhage? | 60 |
| | BÇ | Q 3 | Which imaging examinations are recommended to determine whether reperfusion | |
| | | | therapy is indicated for patients with acute cerebral infarction? | 63 |
| | ΒÇ | Q 4 | Is MRI recommended for diagnosing diffuse axonal injury (DAI)? | 69 |
| | BÇ | Q 5 | Are CT and MRI recommended for diagnosing primary headache in adults? | 72 |
| | BÇ | Q 6 | Which imaging examinations are recommended to diagnose temporal lobe epilepsy? | 75 |
| | ΒÇ | Q 7 | Are MRI and cerebral blood flow SPECT recommended to diagnose Alzheimer's | |
| | | | disease (AD)? | 79 |
| | BÇ | 2 8 | Which imaging examinations are recommended when an intracranial space-occupying | |
| | | | lesion is suspected based on the patient's subacute and chronic clinical course? | 83 |
| | BÇ | 2 9 | Which imaging examinations are recommended to detect metastatic brain tumors? | 87 |
| 2 | H | ead | and Neck | |
| | Sta | anda | rd Imaging Methods for Head and Neck | . 92 |
| | ΒÇ | Q 10 | Is CT recommended for adult sinusitis? | 111 |
| | BÇ | Q 11 | Is MRI recommended for determining the T stage of head and neck cancer? | 114 |
| | BÇ | Q 12 | Is CT recommended for determining the N stage of head and neck cancer? | 118 |
| | BC |) 13 | Is PET recommended for determining the M stage of head and neck cancer? | 120 |

| | BQ 14 | Are CT and MRI recommended for the post-treatment follow-up of head and neck | |
|---|--------|--|-----|
| | | cancer? | 122 |
| | BQ 15 | Is MRI recommended for the qualitative diagnosis of parotid tumors? | 124 |
| | BQ 16 | Is I-131 internal radiation therapy recommended in young patients with thyroid | |
| | | carcinoma? | 126 |
| 3 | Ches | t | |
| | Standa | ard Imaging Methods for Chest | 128 |
| | CQ 1 | Is CT recommended for the differential diagnosis of adult community-acquired | |
| | | pneumonia and non-infectious diseases? | 137 |
| | BQ 17 | Is CT recommended for differentiating between bacterial pneumonia and atypical | |
| | | pneumonia? | 140 |
| | BQ 18 | Is CT recommended for diagnosing pneumoconiosis? | 143 |
| | FQ 1 | Is CT recommended for diagnosing the severity of chronic obstructive pulmonary | |
| | | disease (COPD)? | 145 |
| | BQ 19 | Is expiratory CT recommended for the diagnosis of obstructive pulmonary disease? | 148 |
| | BQ 20 | Is HRCT recommended for diagnosing idiopathic pulmonary fibrosis (IPF)? | 151 |
| | BQ 21 | Is HRCT recommended for differentiating among collagen vascular diseases? | 154 |
| | BQ 22 | Is HRCT recommended for diagnosing drug-induced lung injury? | 158 |
| | FQ 2 | Is CT recommended for diagnosing acute respiratory distress syndrome (ARDS)? | 161 |
| | BQ 23 | Is chest radiography recommended for lung cancer screening? | 164 |
| | CQ 2 | Is low-dose CT recommended for lung cancer screening? | 167 |
| | BQ 24 | Which imaging examinations are recommended for the differential diagnosis of benign and malignant lung nodules? | 171 |
| | CQ 3 | Is FDG-PET/CT recommended for the differential diagnosis of benign and malignant | |
| | | lung nodules? | 174 |
| | BQ 25 | Is CT recommended for determining the T stage of lung cancer? | 176 |
| | CQ 4 | Is MRI recommended for determining the T stage of lung cancer? | 178 |
| | CQ 5 | Is MRI recommended for diagnosing lymph node metastasis of lung cancer? | 182 |
| | BQ 26 | Is PET recommended for N and M staging of lung cancer? | 186 |
| | BQ 27 | Is contrast-enhanced cranial MRI recommended for diagnosing brain metastasis of | |
| | | lung cancer? | 190 |
| | BQ 28 | Is bone scintigraphy recommended for diagnosing bone metastasis of lung cancer? | 193 |
| | BQ 29 | Is PET recommended for detecting lung cancer recurrence? | 195 |
| | BQ 30 | Is MRI recommended for diagnosing mediastinal tumors? | 198 |
| | BQ 31 | Is CT recommended for distinguishing benign from malignant pleural lesions? | 202 |
| | BQ 32 | Is PET/CT recommended for diagnosing malignant pleural mesothelioma? | 205 |

4 Cardiovascular

5

| Standa | ard Imaging Methods for the Cardiovascular Region | . 209 |
|--------|--|-------|
| CQ 6 | When \geq 64-row MDCT is used to investigate acute pulmonary thromboembolism, is | |
| | simultaneous CT venography recommended? | 234 |
| CQ 7 | Is functional testing with FFR-CT recommended if intermediate stenosis is seen by | |
| | coronary CTA performed for effort angina? | 237 |
| CQ 8 | Is MRI T1 mapping recommended for diagnosing left ventricular hypertrophy? | 243 |
| BQ 33 | Are CT and MRI recommended for diagnosing Takayasu's arteritis? | 246 |
| BQ 34 | Are CT and MRI recommended to determine whether TAVI/TAVR is anatomically | |
| | indicated for aortic stenosis? | 251 |
| FQ 3 | Is preoperative identification of the artery of Adamkiewicz recommended before open | |
| | repair or endovascular repair of a thoracic aortic aneurysm or thoracoabdominal aortic | |
| | aneurysm? | 256 |
| BQ 35 | Is nuclear medicine testing recommended for diagnosis and elucidation of pathology in | |
| | patients with chronic heart failure? | 260 |
| Diges | stive Organs | |
| Standa | ard Imaging Methods for Digestive Organs (liver) | . 266 |
| Standa | ard imaging methods (gallbladder and bile duct) | . 278 |
| Standa | ard imaging methods (pancreas) | . 283 |
| Standa | ard imaging methods (gastrointestinal tract) | . 289 |
| BQ 36 | Which imaging examinations are recommended for hepatocellular carcinoma screening | |
| | in patients with chronic liver disease? | 297 |
| CQ 9 | Is EOB-MRI recommended to differentiate HCC from hemangioma for lesions that | |
| | show hypervascularity but no washout in patients with chronic liver disease? | 304 |

| | show hypervaceating out no washout in partents with emotion inver alsouser in | |
|-------|--|-------|
| CQ 10 | Is EOB-MRI recommended to differentiate from hypervascular pseudolesions for | |
| | lesions that show hypervascularity but no washout in patients with chronic liver | |
| | disease? | . 304 |
| CQ 11 | Is EOB-MRI recommended for diagnosing non-hypervascular lesions in patients with | |
| | chronic liver disease? | . 309 |
| CQ 12 | Is periodic follow-up recommended for diagnosing non-hypervascular lesions in | |
| | patients with chronic liver disease? | . 309 |
| BQ 37 | Which imaging findings are used to diagnose classical (hypervascular) HCC? | .315 |
| BQ 38 | Which imaging examinations are recommended for diagnosing liver tumors in patients | |
| | with decreased kidney and liver function? | .318 |
| | | |

| When is the use of extracellular gadolinium contrast media and Gd-EOB-DTPA | |
|---|---|
| recommended for contrast-enhanced MRI of liver tumors? | 321 |
| What are the circumstances in which screening for extrahepatic metastasis of HCC is | |
| recommended, and when it is implemented, what are the recommended target organs | |
| and imaging examinations? | 325 |
| How should the efficacy of molecularly-targeted drugs and radiation therapy for HCC | |
| be evaluated? | 328 |
| Which imaging examinations are recommended to evaluate the efficacy of TACE in | |
| HCC? | 332 |
| Which imaging examinations are recommended to evaluate the efficacy of RFA in | |
| HCC? | 335 |
| Is EOB-MRI recommended for the definitive diagnosis of focal nodular hyperplasia? | 337 |
| Is dynamic CT recommended for diagnosing mass-forming intrahepatic | |
| cholangiocarcinoma? | 341 |
| Is EOB-MRI recommended for diagnosing liver metastasis (metastatic liver tumors)? | 344 |
| Is contrast-enhanced MRI recommended for distinguishing benign from malignant | |
| cystic lesions of the liver? | 348 |
| Which imaging examinations are recommended for determining whether | |
| cholecystocholedocholithiasis is present? | 352 |
| Which imaging examinations are recommended if acute cholecystitis is suspected? | 356 |
| Which imaging examinations are recommended if acute cholangitis is suspected? | 361 |
| Is contrast-enhanced CT recommended when gallbladder cancer is suspected? | 365 |
| Is contrast-enhanced CT recommended when extrahepatic bile duct cancer is | |
| suspected? | 370 |
| Is MRI recommended for diagnosing acute pancreatitis and evaluating its severity? | 375 |
| Is CT recommended for diagnosing chronic pancreatitis? | 378 |
| Are CT and MRI recommended for diagnosing autoimmune pancreatitis (AIP)? | 381 |
| Is contrast-enhanced MRI recommended for the differential diagnosis of pancreatic | |
| masses? | 384 |
| Is diffusion-weighted MRI recommended for diagnosing the benign or malignant | |
| nature of pancreatic tumors? | 387 |
| Is abdominal MRI recommended to detect pancreatic cancer? | 390 |
| Is abdominal MRI recommended to determine pancreatic cancer progression? | 393 |
| Are CT and MRI recommended to determine the malignancy grade of P-NETs? | 396 |
| Which imposing examinations are accommonded when integrinal abstraction is | |
| which imaging examinations are recommended when intestinal obstruction is | |
| suspected? | |
| | which is die die Orektratectural gadofindur contrast inclua and Gu-EOD-DTTA recommended for contrast-enhanced MRI of liver tumors? What are the circumstances in which screening for extrahepatic metastasis of HCC is recommended, and when it is implemented, what are the recommended target organs and imaging examinations? How should the efficacy of molecularly-targeted drugs and radiation therapy for HCC be evaluated? Which imaging examinations are recommended to evaluate the efficacy of TACE in HCC? Which imaging examinations are recommended to evaluate the efficacy of RFA in HCC? Is EOB-MRI recommended for the definitive diagnosis of focal nodular hyperplasia? Is Bob-MRI recommended for diagnosing mass-forming intrahepatic cholangiocarcinoma? Is EOB-MRI recommended for diagnosing liver metastasis (metastatic liver tumors)? Is contrast-enhanced MRI recommended for distinguishing benign from malignant cystic lesions of the liver? Which imaging examinations are recommended if acute cholecystitis is suspected? Which imaging examinations are recommended if acute cholangitis is suspected? Is contrast-enhanced CT recommended when gallbladder cancer is suspected? Is MRI recommended for diagnosing acute pancreatitis and evaluating its severity? Is CT recommended for diagnosing acute pancreatitis? Are CT and MRI recommended for diagnosing autoimmune pancreatitis (AIP)? Is abdominal MRI recommended to determine pancreatic cancer progression? |

| BQ 56 | 6 Which imaging examinations are recommended when colonic diverticulitis is | |
|-------|---|-----|
| | suspected? | 405 |
| BQ 57 | Which imaging examinations are recommended for staging of esophageal cancer? | 407 |
| BQ 58 | Which imaging examinations are recommended for staging of gastric cancer? | 410 |
| BQ 59 | Which imaging examinations are recommended for staging of colorectal cancer? | 413 |
| BQ 60 | Is CT colonography recommended for the local diagnosis of advanced colorectal | |
| | cancer? | 416 |

6 Obstetrics and Gynecology

| Standa | rd Imaging Methods for Obstetrics and Gynecology | . 419 |
|--------|--|-------|
| BQ 61 | Does MRI contribute to diagnosing uterine fibroids? | 434 |
| BQ 62 | Is MRI recommended to diagnose adenomyosis? | 437 |
| BQ 63 | Is MRI recommended to diagnose and manage ovarian endometriotic cysts? | 440 |
| FQ 8 | Is MRI recommended to diagnose deep infiltrative endometriosis? | 440 |
| BQ 64 | Is MRI recommended to evaluate the local progression of cervical cancer? | 444 |
| BQ 65 | Is MRI recommended to evaluate the local progression of endometrial cancer? | 448 |
| FQ 9 | Which imaging examinations are recommended to diagnose uterine sarcoma? | 453 |
| BQ 66 | Is MRI recommended for the qualitative diagnosis of adnexal masses? | 457 |
| FQ 10 | Is MRI recommended to diagnose incidental adnexal masses? | 460 |
| BQ 67 | Is contrast-enhanced CT recommended for evaluating metastases when staging | |
| | gynecological malignancies? | 464 |
| CQ 16 | Is the addition of FDG-PET/CT to diagnostic CT with IV contrast recommended for | |
| | staging or re-staging in gynecological malignancies? | 467 |
| FQ 11 | Does CT or MRI during pregnancy affect the fetus? | 472 |
| FQ 12 | Does contrast medium administration affect the fetus? | 472 |
| FQ 13 | Is it possible to breast-feed after contrast medium administration? | 472 |
| FQ 14 | Which imaging examinations are recommended to diagnose acute abdomen in pregnant | |
| | women? | 476 |
| FQ 15 | Is MRI recommended to diagnose abnormalities of the placenta and umbilical cord? | 480 |

7 Uroradiology

| Standard Protocols for the Urinary Tract | | |
|--|--|-----|
| BQ 68 | Is DMSA scintigraphy recommended to detect renal scarring? | 500 |
| BQ 69 | Is contrast-enhanced CT recommended to evaluate solid renal masses? | 502 |
| FQ 16 | In which cases is MRI recommended to differentiate renal mass lesions? | 505 |
| BQ 70 | Which imaging examinations are recommended for staging renal cancer? | 508 |
| BQ 71 | Is CT recommended when a urothelial tumor of the upper urinary tract is suspected? | 513 |

| | BQ 72 | Is MRI recommended to determine the invasion depth of bladder cancer? | 515 |
|---|--------|---|-----|
| | CQ 17 | Is omitting contrast-enhanced MRI recommended when MRI is performed to detect | |
| | | clinically significant prostate cancer in patients with incipient disease? | 518 |
| | BQ 73 | Is MRI recommended for the local staging of prostate cancer? | 522 |
| | BQ 74 | Is bone scintigraphy recommended for prostate cancer staging and posttreatment | |
| | | follow-up? | 527 |
| | BQ 75 | Which imaging examinations are recommended for staging testicular tumors? | 530 |
| | BQ 76 | Which imaging examinations are recommended for the posttreatment evaluation of a | |
| | | testicular tumor? | 533 |
| | BQ 77 | Which imaging examinations are recommended to diagnose adrenal adenomas? | 536 |
| 8 | Breas | st | |
| | Standa | rd Imaging Methods for Breast | 541 |
| | FQ 17 | Is contrast-enhanced MRI recommended for the qualitative diagnosis of | |
| | | microcalcification without abnormal findings on ultrasonography? | 551 |
| | FQ 18 | Is investigation recommended for incidental breast lesions detected by CT performed | |
| | | for non-breast disease? | 555 |
| | CQ 18 | Is contrast-enhanced breast MRI recommended to determine a treatment strategy | |
| | | before breast cancer surgery? | 557 |
| | FQ 19 | Which imaging examinations are recommended to evaluate the axillary lymph nodes | |
| | | before breast cancer surgery? | 563 |
| | FQ 20 | Is whole-body screening by CT, PET, or PET/CT recommended before breast cancer | |
| | | surgery? | 567 |
| | FQ 21 | Which breast imaging surveillance is recommended for the ipsilateral or contralateral | |
| | | breast of women treated with breast-conserving surgery? | 572 |
| | FQ 22 | Is whole-body imaging recommended for periodic surveillance after surgery for | |
| | | anatomic stage I and II breast cancer? | 576 |
| | | | |

9 Musculoskeletal

| Standa | rd Imaging Methods for Musculoskeletal Resions | . 580 |
|--------|---|-------|
| BQ 78 | Is MRI recommended for diagnosing cervical spondylotic myelopathy? | 610 |
| BQ 79 | Is MRI recommended for diagnosing lumbar disc herniation? | 614 |
| BQ 80 | Is hand and wrist joint MRI recommended for diagnosing rheumatoid arthritis (RA)? | 618 |
| CQ 19 | Is MR arthrography recommended for diagnosing rotator cuff injury? | 621 |
| CQ 20 | Is MR arthrography recommended for diagnosing a glenoid labrum tear? | 624 |
| BQ 81 | Are conventional radiography, bone scintigraphy, and MRI recommended for | |
| | diagnosing idiopathic osteonecrosis of the femoral head? | 627 |

| CQ 21 | Is CT recommended for diagnosing idiopathic osteonecrosis of the femoral head? | 627 |
|-------|--|-----|
| BQ 82 | Is MRI recommended for diagnosing meniscal and cruciate ligament injuries of the | |
| | knee joint? | 632 |
| BQ 83 | Is MRI recommended for diagnosing bone tumors and tumor-like lesions? | 635 |
| CQ 22 | 2 Is contrast-enhanced MRI recommended for diagnosing soft tissue neoplasms and | |
| | tumor-like lesions? | 638 |

10 Pediatric

| Standa | ard Pediatric Imaging Methods | 643 |
|--------|--|-----|
| BQ 84 | In which cases is CT recommended for minor head trauma in children? | 647 |
| BQ 85 | Is neuroimaging recommended for a suspected febrile seizure? | 650 |
| BQ 86 | Is skeletal survey by plain radiography recommended to identify child abuse? | 653 |
| FQ 23 | Is chest CT recommended for diagnosing rib fracture for child abuse? | 653 |
| BQ 87 | In which cases is fetal MRI recommended? | 659 |
| BQ 88 | Which imaging examinations are recommended when retinoblastoma is suspected? | |
| BQ 89 | Which imaging examinations are recommended to diagnose and stage neuroblastomas? 666 | |
| BQ 90 | Is MIBG scintigraphy recommended for the posttreatment follow-up of | |
| | neuroblastomas? | 670 |

11 Nuclear Medicine and Hematology

| BQ 91 | Is FDG-PET recommended to stage malignant lymphoma and diagnose its recurrence? 673 |
|--------|---|
| BQ 92 | Is FDG-PET recommended to assess treatment efficacy for malignant lymphoma?676 |
| CQ 23 | Is the addition of FDG-PET/CT or PET recommended to evaluate the activity of |
| | multiple myeloma (MM) after treatment? |
| Index. | |

Abbreviations

| Abbreviation | Full Term in English |
|--------------|---|
| ADC | apparent diffusion coefficient |
| AUC | area under the curve * Unless otherwise indicated, the AUC is obtained from ROC analysis in this guideline. |
| BQ | background question |
| CHESS | chemical-shift selective |
| CI | confidence interval |
| CQ | clinical question |
| СТ | computed tomography |
| СТА | computed tomography angiography |
| EOB-MRI | Gd-EOB-DTPA enhanced MRI |
| EPI | echo planar imaging |
| ERCP | endoscopic retrograde cholangiopancreatography |
| ERP | endoscopic retrograde pancreatography |
| ETL | echo train length |
| EUS | endoscopic ultrasonography |
| FA | flip angle |
| FDG | fluorodeoxyglucose |
| FLAIR | fluid attenuated inversion recovery |
| FOV | field of view |
| FQ | future research question |
| FSE | fast spin echo |
| Gd-EOB-DTPA | gadolinium ethoxy-benzyl diethylene triamine penta-acetic acid |
| GRE | gradient echo |
| HASTE | half-Fourier single-shot turbo spin echo |
| HRCT | high-resolution computed tomography |
| HU | Hounsfield unit |
| IR | inversion recovery |
| MDCT | multi-detector row CT |
| MIBG | meta-iodobenzylguanidine |
| MIP | maximum intensity projection |
| MPR | multi planar reconstruction |
| MRA | magnetic resonance angiography |
| MRCP | magnetic resonance cholangiopancreatography |

| Abbreviation | Full Term in English |
|--------------|---|
| MRI | magnetic resonance imaging |
| NEX | number of excitations |
| РЕТ | positron emission tomography * Unless otherwise indicated, ¹⁸ F-FDG is used for PET and PET/CT in this guideline. |
| ROC | receiver operating characteristic |
| SAR | specific absorption rate |
| SE | spin echo |
| SNR | signal-to-noise ratio |
| SPAIR | spectral attenuated inversion recovery |
| SPECT | single photon emission computed tomography |
| SPIR | spectral inversion recovery |
| SROC | summary receiver operating characteristic |
| SSFP | steady-state free precession |
| SSFSE | single shot fast spin echo |
| STIR | short TI inversion recovery |
| SUV | standardized uptake value |
| Т | tesla |
| ТЕ | echo time |
| TR | repetition time |
| VR | volume rendering |
| WL | window level |
| WW | window width |